POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia.

Saved in:
Bibliographic Details
Title: POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia.
Authors: Gil Rojas, Y1 (AUTHOR), Lasalvia, P2 (AUTHOR), Garcia Peña, AA3 (AUTHOR)
Source: Value in Health. 2022 Supplement, Vol. 25 Issue 1, pS91-S92. 2p.
Database: Academic Search Ultimate
Description
ISSN:10983015
DOI:10.1016/j.jval.2021.11.433